Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Cristina Helguera Amezua , Laura Pérez Bacigalupe , Diego Manuel de la Eranueva , et al Added: 1 month ago

Prevention & Chronic Conditions

Anticoagulation
SCAI 25: Insights from the TRITAVI Registry
Author(s): Francesco Pelliccia Added: 1 year ago
SCAI 2025 - Insights from antiplatelet therapy after transcatheter aortic valve replacement (TAVR) show patients who received single antiplatelet treatment had significantly lower rates of overall six-month mortality, CV death and non-CV death compared to those treated with double antiplatelet treatment.Dr Francesco Pelliccia (Sapienza University of Rome, Rome, IT) joins us to discuss insights… View more

Anticoagulation

Intervention
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 1 year ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
Sex Influences DAPT De-escalation Outcomes Post-PCI
Added: 2 weeks ago Source:  Interventional Cardiology
De-escalation of dual antiplatelet therapy (DAPT) is a strategy used to improve outcomes after percutaneous coronary intervention (PCI).¹˒² However, the impact of patient sex on the safety and efficacy of these strategies has been unclear. A new network meta-analysis published in the European Heart Journal has investigated these potential differences.¹MethodologyThe study analysed data from 20… View more

Intervention

Anticoagulation
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 1 year ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
Author(s): Manav Sohal Added: 1 year ago

Anticoagulation

Electrophysiology & Arrhythmia
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 year ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention